Request a representative visit or G7 15 Day or G7 samples
See emerging Dexcom CGM clinical data and outcomes
Stay on top of compelling clinical evidence
Bookmark this page and check back for the latest updates.
Dexcom presented groundbreaking results at ADA 2026 Scientific Sessions
Watch the video recap to see what this evidence means for your patients. Scroll down to explore the full CONNECT trial findings and understand the clinical implications for your practice.
-
CONNECT Trial
The CONNECT Clinical Trial
CONNECT is the latest and largest RCT that demonstrated significant A1C reduction in people with diabetes not using insulin but using rtCGM worn continuously. As of June 2026, the CONNECT trial is the strongest evidence in this category.1,2
Study Design
The CONNECT trial is the first ever multi-center, randomized, controlled trial (N=283) using Dexcom CGM Systems as the intervention for type 2 non-insulin taking patients, conducted over 26 weeks at >22 primary care practices in the US. Subjects received diabetes education (diet and exercise), a blood glucose meter, and continued pre-study glucose-lowering medications (40% were using GLP-1).
The most significant clinical trial demonstrating CGM benefits for people with type 2 diabetes not using insulin2
Patients in CONNECT who used Dexcom CGM had lower mean A1C after 26 weeks than
those with only routine care and no CGM use.2
Explore more outcomes among patients with type 2 diabetes not on insulin
Patients in the Dexcom CGM arm reported a 97% rate of daily CGM
use vs. 41% of daily SMBG use for the control group.2
Over 2x
Over 2x more patient engagement
with Dexcom CGM vs. routine care (SMBG)2
97% median daily
Dexcom CGM usagethroughout the 26 weeks2
41% daily SMBG use
in the control group2
The non-insulin glucose-lowering concomitant medications allowed in the CONNECT trial included metformin, GLP-1 alone, and SGLT2 both with and without GLP-1.2 82% of patients in the CGM group improved their A1C by at least 0.5%.2
Change in A1C, grouped by non-insulin glucose-lowering medications in use at baseline2
Glucose-lowering medication at baseline
Explore more outcomes among patients with type 2 diabetes not on insulin
Nearly half of
CONNECT participantsachieved A1C <7.0% at 6 months*,2
Patients in the Dexcom CGM group showed a 21% increase in time in range compared with those using routine care alone.2
Patients in CONNECT who used Dexcom CGM had more TIR than those on routine care alone2
Explore more outcomes among patients with type 2 diabetes not on insulin
TIR increase
on average with Dexcom CGM2
increase in TIR
CGM vs. routine care (SMBG)2
-
Hirsch Study
Study Design
Continuous glucose monitoring frequency and glycemic control in people with type 2 diabetes (Hirsch 2025). Retrospective, propensity score–matched, cross-sectional study used Optum deidentified Market Clarity Data (claims and electronic medical record data) obtained between January 1, 2019, and December 31, 2023, including data from 6 months prior to each participant's index date with 12 months follow-up. Participants (N=9258) with type 2 diabetes >18 years treated with non-insulin, basal insulin, and/or prandial insulin therapy. Baseline A1C levels between 7.0% to 15.0% were included with a median age of 56 years. Data compared A1C differences between patients with low/no CGM use vs. those with frequent CGM use. Benefits were observed across treatment regimens, including non-insulin, basal, and prandial insulin therapy.3
The Hirsch study demonstrated that daily CGM use improved glycemic outcomes3
In a recent study of patients with type 2 diabetes the endpoint was change in A1C relative to frequency of CGM use vs. no CGM. Patients who used CGM most often achieved the lowest A1C levels.3
CGM + glucose-lowering medications lead to
greater reductions than with medications alone3See the data from patients with type 2 diabetes from 4 different study populations (GLP-1 RA, SGLT2i, basal insulin, and prandial insulin) who added CGM to their medications and significantly lowered their A1C levels.
Adapted from Hirsch IB, et al. JAMA Netw Open. 2025;8(10):e2539278.
Explore more outcomes in adults with type 2 diabetes
GLP-1 + Dexcom CGM
See how adding Dexcom CGM improves GLP-1 outcomes
SGLT2i + Dexcom CGM
Dexcom CGM boosts SGLT2i results
Basal insulin + Dexcom CGM
Even patients on insulin do better with Dexcom CGM
A1C=hemoglobin A1C; ADA=American Diabetes Association; CGM=continuous glucose monitoring; GLP-1=glucagon-like peptide-1; GLP-1 RA=glucagon-like peptide-1 receptor agonist; isCGM=intermittently scanned continuous glucose monitoring; RCT=randomized controlled trial; rtCGM=real-time continuous glucose monitoring; SGLT2=sodium-glucose cotransporter 2; SGLT2i=sodium-glucose cotransporter 2 inhibitor; SMBG=self-monitoring of blood glucose; TIR=time in range.
*46% of patients in the CGM group achieved A1C <7.0% compared to 24% in the routine care group.
References: 1. Ferreira R, et al. Diabetes Technol Ther. 2024;26(4):252-262. 2. Martens T. Presented at ADA 2026 Scientific Sessions. June 6, 2026. New Orleans, LA. 3. Hirsch IB, et al. JAMA Netw Open. 2025;8(10):e2539278.
MAT-16470